This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sepilian, V. Articles by Nagamani, M. Search for Related Content PubMed PubMed Citation Articles by Sepilian, V. Articles by Nagamani, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Obesity Hazardous Substances DB TESTOSTERONE Social Bookmarking                         What's this?

Adiponectin Levels in Women With Polycystic Ovary Syndrome and Severe Insulin Resistance

Department of Obstetnics and Gynecology, University of Texas Medical Branch, Galveston, TX 77555-0587; mnagaman{at}utmb.edu

Manubai Nagamani, MD

Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, University of Texas Medical Branch, Galveston, Texas

Objective: Adiponectin is an adipokine that is decreased in obesity and type 2 diabetes. Women with polycystic ovarian syndrome (PCOS) are obese and are at risk for type 2 diabetes. The objective of the current study was to investigate the relationship of adiponectin to obesity and insulin resistance in women with PCOS and severe insulin resistance.

Methods: Thirty women with PCOS and acanthosis nigricans indicating severe insulin resistance were included in the study. Eleven body mass index (BMI)-matched women with normal ovulatory cycles served as controls. Fasting glucose, insulin, and adiponectin levels were measured, and a standard oral glucose tolerance test (OGTT) with insulin levels was performed. To further investigate the role of insulin sensitivity on adiponectin levels, 10 women with PCOS were treated with 4 mg rosiglitazone daily for 6 months and adiponectin levels were measured before and after treatment.

Results: Fasting insulin levels (33.5 ± 3.8 µU/mL; P <.001) and insulin area under the curve (AUC) during OGTT (536.2 ± 70.5 µU/mL; P <.01) were higher in women with PCOS, while glucose levels were similar to controls. Adiponectin levels were lower (P <. 01) in women with PCOS (5.6 ± 2.6 µg/mL) compared with controls (8.5 ± 3.9 µg/mL). There was a significant negative correlation between adiponectin levels and fasting insulin levels (r =-0. 40, P =. 02), insulin AUC during OGTT (r =-0.47, P = .008),fasting glucose levels (r =-0.45, P = .01), andglucoseAUC during OGTT (r =-0.51, P = .003). There was no correlation between BMI and serum adiponectin (r =-0.12, P = .508) in women with PCOS, while there was a negative correlation (r =-0.746, P = .013) in controls. There was a significant (P <.01) increase in adiponectin levels when treated with rosiglitazone, despite unchanged BMI.

Conclusion: These results indicate that in women with PCOS and severe insulin resistance, insulin sensitivity appears to be the major determinant of adiponectin levels rather than adiposity. Low adiponectin levels may predict women with PCOS who are at high risk for developing type 2 diabetes.

Key Words: Adiponectin • PCOS • insulin resistance • adipokines

Journal of the Society for Gynecologic Investigation, Vol. 12, No. 2, 129-134 (2005)
DOI: 10.1016/j.jsgi.2004.09.003


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H.F. Escobar-Morreale, G. Villuendas, J.I. Botella-Carretero, F. Alvarez-Blasco, R. Sanchon, M. Luque-Ramirez, and J.L. San Millan Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study Hum. Reprod., September 1, 2006; 21(9): 2257 - 2265. [Abstract] [Full Text] [PDF]